Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 13/20 | 0.52 |
| ▸ | F13A1 | P00488 | 10/20 | 0.52 |
| ▸ | TGM1 | P22735 | 7/20 | 0.52 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19869960 | 0.88 | TGM2 (0.65) | TGM2F13A1TGM1TGM3LMNA | |
| SCHEMBL5442261 | 0.84 | TGM2 (0.52) | TGM2F13A1TGM1TGM3EPHX2 | |
| SCHEMBL5442111 | 0.84 | TGM2 (0.64) | TGM2F13A1TGM1TGM3EPHX2 | |
| SCHEMBL2226727 | 0.83 | TGM2 (0.64) | TGM2F13A1TGM1TGM3LMNA | |
| SCHEMBL1156581 | 0.83 | ADRA2A (0.50) | ADRA2ANPY5RMCHR1LMNAOPRM1 | |
| SCHEMBL14490312 | 0.82 | TGM2 (0.52) | TGM2F13A1TGM1TGM3EPHX2 | |
| SCHEMBL14490211 | 0.81 | TGM2 (0.61) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL3018182 | 0.81 | GAA (0.57) | ADRA2ANPY5RMCHR1LMNAOPRM1 | |
| SCHEMBL25176606 | 0.81 | TGM2 (0.51) | TGM2F13A1TGM1TGM3LMNA | |
| SCHEMBL16013381 | 0.81 | GAA (0.65) | TGM2F13A1TGM1TGM3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007056075-A2 | SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS | TARGEGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | TGM2 1975/4885F13A1 4382/4885TGM1 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.